Elemind, a neurotech wellness company, has introduced a revolutionary headband that harnesses advanced neurotechnology to improve sleep quality. The device reads brainwaves in real-time and directs them from wakeful patterns into a deeper sleep state.
In a clinical trial, 76% of participants experienced a faster time to fall asleep, with an average reduction of 48%. The maximum improvement observed was 74% faster.
Elemind’s patented algorithm and neurotech empower users to “start and restart sleep,” providing greater control over their slumber. This innovative approach addresses a widespread need in the sleep industry: the ability to regulate the sleep process.
Unveiled after five years of research and clinical trials, Elemind’s headband utilizes neurostimulation to measure brain activity and deliver targeted acoustic waves. This approach effectively moves the brain from wakeful patterns into a deeper sleep state.
Unlike traditional sleep drugs, Elemind operates in real-time without harmful side effects. It swiftly optimizes sleep time, outperforming leading sleep drugs but without the need for medication.
The headband’s advanced neuromodulation technology is seamlessly embedded into a comfortable design, enabling wearers to experience its benefits regardless of their sleep position. The headband can be used anytime, day or night, to initiate or enhance sleep.
Elemind’s smartphone application provides advanced sleep data and analytics, including sleep performance, efficiency, and duration. The app also features the AI Sleep Tailor, personalizing the system’s effectiveness over time.
By harnessing the power of neuroscience, Elemind empowers individuals to take control of their sleep and enhance their overall well-being through a natural, drug-free approach.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
